Sunshine Coast Health Institute, University of the Sunshine Coast, Birtinya, QLD 4575, Australia
Nearly two-fifths (37 per cent) of Canadian employers cover glucagon-like peptide-1 therapies for both diabetes and weight loss, up from 31 per cent in 2025 and just 17 per cent in 2024, according to a new survey by the International Foundation of Employee Benefit Plans
Healthspan does not endorse these views, nor should they be regarded as health claims or medical advice
After seven days, roughly 38% of the previous dose remains, compared to about 50% for semaglutide
Consultation with Physician Once we have your lab results, one of our team members will reach out to you to schedule a consultation with the physician to discuss lab results and treatment plan